Načítá se...

Evaluation of Alpha-Therapy with Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—the Role of Gamma Scintigraphy in Dosimetry and Pharmacokinetics

Radium-223-dichloride ((223)RaCl(2)) is a new bone-seeking calcium analogue alpha-emitter, which has obtained marketing authorization for the treatment skeletal metastases of hormone-refractory prostate cancer. The current treatment regimen is based on six consecutive doses of (223)RaCl(2) at 4 week...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Diagnostics (Basel)
Hlavní autoři: Kairemo, Kalevi, Joensuu, Timo, Rasulova, Nigora, Kiljunen, Timo, Kangasmäki, Aki
Médium: Artigo
Jazyk:Inglês
Vydáno: MDPI 2015
Témata:
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4665607/
https://ncbi.nlm.nih.gov/pubmed/26854158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/diagnostics5030358
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!